DermaSensor appoints trio of new executives

[Image from DermaSensor]Skin cancer detection technology developer DermaSensor announced that it appointed three new members to its leadership team.

Miami-based DermaSensor named Larry Anderson as its new chief commercial officer. Dr. Vivien Nguyen also joins as director of medical affairs, while the company promoted Ryan Freiden to COO.

Anderson previously served as VP of sales for Acessa Health, which Hologic acquired. He also held roles at Ethicon, Interlace Medical, Hologic and BG Medical.

“It gives me great pleasure to introduce Larry Anderson as our chief commercial officer,” DermaSensor CEO Cody Simmons said in a news release. “Larry has extensive commercial experience in the medical device field with a strong track record of successfully building teams and launching new technologies.”

Nguyen joins with nearly a decade of experience in medical devices and pharmaceuticals. She held roles at Incyte, Novartis, Suneva Medical and…

Read more
  • 0

They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]

Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Read on to hear what medtech leaders had to say at DeviceTalks Boston 2022.

Next >>

Read more
  • 0

DermaSensor raises $10M as it braces for U.S. launch

[Image from DermaSensor]DermaSensor announced today that it raised an additional $10 million as it prepares for a commercial launch in the U.S.

Miami, Florida-based DermaSensor’s $10 million fundraising accompanies news that the company met all primary endpoints for two FDA pivotal studies, setting it up to potentially offer the only FDA-cleared, automated skin cancer detection tool on the market that uses any kind of imaging or optical technology.

The DermaSensor device received FDA breakthrough device designation in 2021, and the company expects it to become the first device cleared by the FDA to assist PCPs in evaluating skin cancer.

According to a news release, the device uses a form of optical spectroscopy (called elastic scattering spectroscopy, or ESS) to take non-invasive samples of tissue, capturing cellular-level information from the skin lesion using hundreds of wavelengths of light in a manner similar to how sonar uses sound.

It pro…

Read more
  • 0

DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event

DermaSensor can evaluate a skin lesion for skin cancer risk in under 30 seconds, according to the company. [Image courtesy of DermaSensor]DermaSensor — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.

The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with a cash prize and admission to MedTech Innovator and its host of benefits.

DermaSensor’s device uses optical spectroscopy. A light-emitting tip non-invasively touches the lesion, receiving and analyzing data from below the skin at cellular and subcellular levels. The technology could help general practitioners better spot lesions that are potential problems before forwarding their patients to a dermatologist for further evaluation.

Research involving 57 general practitio…

Read more
  • 0